Pulmonary exacerbations as a risk factor for lung function decline – experiences of the National Cystic Fibrosis Center

Egzacerbacije plućne bolesti kao faktor rizika od sniženja funkcije pluća – iskustva Nacionalnog centra za cističnu fibrozu

Bojana Z. Gojšina*, Milan Rodić†, Jelena Višekruna†, Goran Z. Trajkovič*†, Aleksandar D. Sovtič†, Predrag B. Minič*†

University of Belgrade, *Faculty of Medicine, Belgrade, Serbia; Mother and Child Health Institute “Dr Vukan Ćupić”, †Department of Pulmonology, Belgrade, Serbia; University of Belgrade, Faculty of Medicine, *Institute for Medical Statistics, Belgrade, Serbia

Abstract

Background/Aim. Pulmonary exacerbations have negative impact on clinical course of cystic fibrosis (CF) lung disease being associated with a steeper decline in the lung function, unfavorable prognosis and impaired quality of life. The aim of this study was to determine whether an increased number of exacerbations had influence on the lung function in the patients with CF, as well as to estimate the nutritional status, gender, presence of comorbid conditions and bacterial colonization of airways as predictive factors for pulmonary exacerbations.

Methods. This retrospective cohort study included 83 pediatric and adult patients, treated from 2011–2015 in the Mother and Child Health Institute of Serbia „Dr Vukan Ćupić“. The best result of forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) in each year of follow-up was taken into account to calculate the five-year trend values of these indicators. The number of exacerbations per year of follow-up and its impact on the FEV1 decline was evaluated. Results. Mean annual decline of FEV1 and FVC were 2.4% and 1.7% respectively. The malnourished patients had the lower initial values of FEV1 and FVC, and more frequent exacerbations in comparison with the normal weight and overweight patients. The frequency of exacerbations was significantly higher in the patients chronically colonized with *Burkholderia cepacia* (√p = 0.023). The increased number of exacerbation was proved to be the most important factor in a prediction of FEV1 decline over time (√p = 0.013). Conclusion. Pulmonary exacerbations lead to the more progressive lung function decline in the patients with CF. Malnourishment and chronic airway colonization with *Burkholderia cepacia* result in more frequent pulmonary exacerbations.

Key words: *burkholderia cepacia; cystic fibrosis; forced expiratory volume; lung diseases; recurrence; respiratory function tests.*

Apstrakt

Uvod/Cilj. Egzacerbacije plućne bolesti imaju negativan uticaj na klinički tok cistične fibroze (CF), a njihova veća učestalost povezuje se sa izraženijim sniženjem vrednosti funkcije pluća i lošijim kvalitetom života. Cilj ovog istraživanja bio je da se utvrdi uticaj broja egzacerbacija na trend funkcije pluća kod obolestih od CF, kao i značaj stanja uhranjenosti i pola ispitanika, komorbidnih stanja i kolonizacije disajnih puteva patogenim bakterijama na trend funkcije pluća i učestalost egzacerbacija plućne bolesti. Metode. Istraživanjem su obuhvaćena 83 ispitanika, deca i odrasle osobe, obolela od CF, lečena u periodu od 2011. do 2015. godine u Institutu za zdravstvenu zaštitu majke i deteta Srbije „Dr Vukan Ćupić“. Najbolji rezultat foriranog ekspiratnog volumena u prvoj sekundi (FEV1) i foriranog vitalnog kapaciteta (FVC) svake godine pružen je u obzir pri računanju petogodišnjeg trenda vrednosti ovih pokazatelja. Procenjivan je broj egzacerbacija po godini praćenja i ukupan broj na kraju perioda praćenja. Rezultati. Prosечно smanjenje vrednosti FEV1 bilo je 2,4%, a FVC 1,7% godišnje. Neuhranjeni ispitanici su imali nižu vrednost FEV1 i FVC i veći broj egzacerbacija u odnosu na normalno i prekomernu uhranjene (p = 0,001). Učestalost egzacerbacija je bila statistički značajno viša kod ispitanika hronično kolonizovanih bakterijom *Burkholderia cepacia* (p = 0,023). Povećanje broja egzacerbacija bilo je statistički najznačajniji predikтивni činilac pogorsanja FEV1 u posmatranom periodu (p = 0,013). Zaključak. Veća učestalost egzacerbacija plućne bolesti kod obolestih od CF dovodi do izraženijeg...
smanjenja vrednosti parametara funkcije pluća. Niže vrednosti funkcije pluća imaju neuhranjeni bolesnici in bolesnici kolonizovani bakterijom Burkholderia cepacia čije prisustvo dovodi do češčih egzacerbacij plućne bolesti.

**Introduction**

Cystic fibrosis (CF) is the most frequent autosomal recessive disease in the Caucasians. In its typical form, CF is manifested by failure to thrive, repeated lung infections and impaired mucus clearance which leads to suppurative lung disease, characterized by a decline in the lung function during a lifetime, which gradually progresses to respiratory insufficiency. Recent data show that the mean life expectancy in the USA is 40 years and in Serbia is around 30 years. Many factors contributed to a significant life prolongation and improvements of quality of life. Among these factors, the major influence have an early diagnosis, especially by introduction of neonatal screening programmes, hypercaloric diet and efficient treatment of pulmonary exacerbations (PE). A clinical stage of the disease can be expressed by several indicators (biomarkers) whose standardization enables an objective assessment of a patient’s condition and final outcome. The most commonly used biomarker is the value of the forced expiratory volume in the first second (FEV1), which is influenced by the frequency and course of PE. Although there is no widely used standardized definition of PE, the ideal definition should cover the objective clinical, biochemical and physiological factors. In clinical research settings, the hospitalization and intravenous use of antibiotics are listed as the undeniable indicators. PE is characterized by the increased cough and sputum production, haemoptysis, fever, loss of appetite and weight loss, dyspnea, tachypnea, exercise intolerance and sinus discharge. It was shown that more frequent exacerbations led to a steeper lung function decline, poorer quality of life and earlier fatal outcome.

In the patients with CF, in an ideal clinical course, the annual decrease of FEV1 is about 2%. In a majority of patients, PE is associated with a significant reduction in lung function, with gradual, but often not complete recovery thereafter. In 25% of cases, the lung function decline persists, despite the aggressive systemic antimicrobial therapy.

A favorable clinical response to the treatment is FEV1 recovery to ≥ 90% of the baseline value. Certain risk factors can contribute to an unfavorable outcome and partial recovery besides initially lower lung function. These risk factors are: female gender, impaired glucose tolerance, chronic colonization of respiratory tract with specific bacterial pathogens e.g. Pseudomonas aeruginosa (P. aeruginosa) or Burkholderia cepacia (B. cepacia) and initially lower FEV1 values. Despite the novel treatment modalities, the incidence of PE did not significantly decreased in the last two decades.

The aim of the study was to determine if an increased number of exacerbations during the five-years period had influence on the lung function in our cohort of patients with CF. Additionally, we evaluated if the nutritional status, evidence of comorbid conditions and bacterial colonization of airways affect the lung function decline and if they can be used as the predictive factors for PE.

**Methods**

This retrospective cohort study included 110 pediatric and adult patients. All patients were treated at the national CF center – Mother and Child Health Institute of Serbia “Dr Vukan Ćupić”. The demographic data, current therapy, bacterial colonization of lower airways and lung function results were obtained from the European CF registry and patient’s medical history files. The patients performed the regular physical therapy on daily basis during the study. The best annual values of FEV1 and forced vital capacity (FVC) were taken into account in calculating the five-year trend value of these indicators. The number of exacerbations per year and the total number at the end of the monitoring period were evaluated for each patient. Nutritional status was estimated according to the Z score of body mass index (BMI). The patients were stratified into three groups: (underweight – BMI < 18.5 [or ≤ 1 standard deviation (SD)] kg/m2 normal weight – BMI 18.5-24.9 (-1+1 SD) and overweight – BMI > 24.9 (or ≥ 1 SD) kg/m2).

The descriptive statistics, including mean and standard deviation of numerical variables, and frequencies and percentages of categorical variables were used to characterize the study sample. Differences between groups regarding the numerical variables were analyzed by use of the Kruskal-Wallis test, while the Fisher exact test or the Pearson’s χ2 test were used for the categorical variables. The linear regression models were used to assess relationship between the number of exacerbations, or changes of FEV1, as the dependent variables and the independent variables. The R environment for statistical computing (R Core Team, 2016) was used to conduct the statistical analyses. A significance level (alpha level) was set at 0.05.

**Results**

Data of 83 patients out of the 110 screened ones were included in the analysis. Others (27 patients) were excluded from the analysis due to the incomplete medical records. The average age of patients at the beginning of the follow-up period was 17.1 ± 7.1 years, and the average age at the time of diagnosis was 3.7 ± 4.3 years, with similar sex distribution. A majority of study participants had normal weight, with the average Z score of BMI of -0.97 ± 1.4 SD.

During the five year of follow-up, the subjects had an average of 0.6 exacerbations annually. Other demographic data are shown in Table 1.
### Table 1
**Demographic data of patients with cystic fibrosis**

| Variable                          | Value     |
|----------------------------------|-----------|
| Gender, n (%)                    |           |
| male                             | 42 (51)   |
| female                           | 41 (49)   |
| Age (years), mean ± SD           | 17.1 ± 7.1|
| Age at diagnosis (years), mean ± SD | 3.7 ± 4.3 |
| BMI (kg/m²), mean ± SD           | 18.1 ± 3.5|
| Z score BMI, mean ± SD           | -0.97 ± 1.4|
| Colonization with *Pseudomonas aeruginosa*, n (%) | 53 (62) |
| Colonization with *Burkholderia cepacia*, n (%) | 10 (12) |
| Diabetes, n (%)                  | 12 (14)   |
| Asthma, n (%)                    | 23 (27)   |
| Liver disease, n (%)             | 17 (20)   |

n – number of patients; BMI – body mass index; SD – standard deviation.

The average decrease of FEV₁ in the five-year period was 11.9% ± 14.5%, and annual decrease was 2.4% ± 2.9%. The average decrease of FVC was 8.6% ± 1.8%, and 1.7% ± 3.6% respectively. The annual decrease of FEV₁ and FVC was not different in regard to the patient’s sex (p = 0.2 and p = 0.7, respectively).

The underweight patients had the significantly lower values of FEV₁ in comparison with the normal and overweight patients (p = 0.001). Similar difference was shown between the groups according to the FVC values (p < 0.001).

Furthermore, in the underweight subjects, exacerbations were more frequent over five years of follow-up compared to other two groups (p = 0.02) (Table 2).

### Table 2
**The lung function and frequency of exacerbations in the patients with cystic fibrosis according to the nutritional status**

| Parameter | Underweight (n = 40) | Normal weight (n = 38) | Overweight (n = 4) | p   |
|-----------|----------------------|------------------------|--------------------|-----|
| FEV₁ (%)  | 64.0 ± 24.4          | 83.7 ± 24.4            | 91.5 ± 17.2        | 0.001|
| FVC (%)   | 71.2 ± 20            | 90.3 ± 19              | 98.3 ± 12.5        | <0.001|
| Average annual number of exacerbations during the study | 0.8 | 0.5 | 0.0 | 0.02 |

FEV₁ – forced expiratory volume in the first second; FVC – forced vital capacity; SD – standard deviation; p – value for statistical significance defined as p < 0.05.

### Table 3
**Regression models with dFEV₁ as a dependent variable**

| Variable | Univariate regression models | Multiple regression models |
|----------|------------------------------|----------------------------|
|          | B    | p    | B    | p    |
| Age at diagnosis | -0.21 | 0.587 |          |       |
| Initial FEV₁% value | 0.02 | 0.796 |          |       |
| Number of exacerbations | -7.22 | 0.002* | -6.10 | 0.013* |
| Z score BMI | 2.75 | 0.028* | 1.77 | 0.158 |
| Asthma | 5.26 | 0.145 |          |       |

FEV₁ – forced expiratory volume in the first second; dFEV₁ – FEV₁ – decline in the five-years follow-up; BMI – body mass index. * – statistically significant.
Discussion

Exacerbations of lung disease are significant factor of morbidity that affects decline in the lung function in the patients with CF. We showed that the most significant risk factor for the exacerbation occurrence in our cohort of patients was chronic airway colonization with *B. cepacia*.

The natural course of CF lung disease is characterized by a gradual deterioration with the intermittent episodes of acute endobronchial infection. The lung function mostly has steeper decline in the female patients from adolescence, which was not the case in our study. Exacerbations of pulmonary disease present a major burden for the patients and their families with a negative affection on quality of life. Due to inexistence of dedicated home care providers, all patients in Serbia are hospitalized for the intravenous antibiotic therapy in accordance with previous studies. Exacerbations of pulmonary exacerbations lead to prolongation of hospital stay and intensive physical rehabilitation. The burden is even more significant for the health system, as antimicrobial therapy in hospital significantly increases medical expenses. In a large observational study, which involved more than 11,000 patients, 42% of patients had exacerbation during a six-months follow-up. In the etiology of exacerbation, the respiratory viruses play an important role by reactivation of chronic bacterial infection in the lower respiratory tract with common CF pathogens such as *P. aeruginosa* or *Staphylococcus aureus*, which lead to prolongation of hospital stay.

Despite the high prevalence of chronic *Pseudomonas* colonization in our cohort (62%), it was not shown to be a significant predictor of appearance of PE. The patients with the higher exacerbation score and shorter interval between it, had a greater overall FEV₁ decline. Our research in the relatively heterogeneous CF population confirmed that the increased number of exacerbations correlated with a more significant loss of lung function. The annual FEV₁ decline in our cohort was 2.4%, which was significantly higher compared to the results of other studies (1.8%–2%). Although the treatment of patients with CF in our country is mostly performed without delay in a specialized center according to the international guidelines, there are several reasons which may explain this negative trend.

The most likely reasons are malnutrition and a high prevalence of chronic *Burkholderia* colonization, which is in accordance with previous studies. Colonization with *B. cepacia* is associated with higher mortality and morbidity, including more frequent exacerbations, weight loss and rapid lung function decline. The patients colonized with *B. cepacia* in our cohort had the higher exacerbation score. Association of chronic *B. cepacia* colonization with malnutrition, leads to more frequent exacerbations compared to the patients with normal weight.

The results of large cohort study showed that the nutritional status and pulmonary function are the dependent variables in CF, which is in concordance with our results. More frequent PE and steeper decline in the lung function in the malnourished patients is directly related to the poorer prognosis and unfavorable outcome.

Conclusion

Pulmonary exacerbations lead to a progressive lung function decline in the patients with CF over time. Malnourishment and chronic airway colonization with *B. cepacia* result in more frequent PE.

The objective assessment of the symptoms and signs of PE allows vigorous antimicrobial therapy. This usually leads to a favorable clinical course with preservation of the lung function, which is an important indicator of respiratory health in the patients with CF.

**References**

1. Amadori A, Antonelli A, Balteri I, Schreiber A, Bagiani M, Dr. Rose V. Recurrent exacerbations affect FEV₁ decline in adult patients with cystic fibrosis. Respir Med 2009; 103(3): 407–13.
2. Zadravković D. Problemi u pedijariji. Beograd: Zavod za udžbenike; 2011. (Serbian).
3. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373(9678): 1891–904.
4. Waterson V, Stanojevic S, Atanasiu EG, La A, Yan Y, Tulis E, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012; 40(1): 61–6.
5. Dukin C, Henry RL, Field P, Martin J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001; 31(6): 430–42.
6. Waterson V, Rajen F. Pulmonary Exacerbations in Children with Cystic Fibrosis. Am Am Thorac Soc 2015; 12 Suppl 2: S200–6.
7. Waterson V, Stanojevic S, Klingel M, Chiang J, Sunnerveld N, Kukkar R, et al. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J Cyst Fibros 2015; 14(6): 770–7.
8. de Boer K, Vandemheen KL, Tulis E, Doncette S, Ferguson D, Freitag A, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011; 66(8): 680–5.
9. Waterson VJ, Stanojevic S, Sunnerveld N, Klingel M, Graesemann H, Yan YG, et al. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros 2015; 14(6): 755–62.
10. Bhattacharya J. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 2013; 22(129): 205–16.
11. Rahim HR, Butler SM, Wold ME, Geller DE, Colin A.A, Schilling DV, et al. Epidemiologic Study of Cystic Fibrosis. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004; 37(5): 400–6.
12. Elborn JS, Flume P,A, Cohen F, Luntt J, VanDevanter DR. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic *Pseudomonas* aeruginosa airway infection. J Cyst Fibros 2016; 15(5): 634–40.
13. Vasiljevic ZV, Novovic K, Kojic M, Martina P, Feliziani S, Juan C, Bettiol M, Gatti B, Yantorno O, et al. Burkholderia cepacia complex in Serbian patients with cystic fibrosis: prevalence and molecular epidemiology. Eur J Clin Microbiol Infect Dis 2016; 35(8): 1277–84.
14. Folete TN, da Costa CH, Cohen RF, da Conceição Neto OC, Albano RM, Marques F.A. Burkholderia cepacia complex: clinical course in cystic fibrosis patients. BMC Pulm Med 2015; 15: 158.
15. Martina P, Fedrigioni S, Juan C, Bettiol M, Gatti B, Yantorno O, et al. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly preva-
lent in cystic fibrosis chronic respiratory infection. Int J Med Microbiol 2014; 304(8): 1182–91.

16. Tullis DE, Burns JL, Retich-Bogart GZ, Bresnik M, Henig NR, Lewis SA, et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros 2014; 13(3): 296–305.

17. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 2002; 57(7): 596–601.

Received on October 14, 2017.
Accepted on January 15, 2018.
Online First January, 2018.